Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.

Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.

Item
http://www.wikidata.org/entity/Q35097203
GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion ProcessEvaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.Human rhinoviruses in severe respiratory disease in very low birth weight infants.The burden of respiratory syncytial virus infection in young childrenTrends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registriesPalivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Prophylaxis of respiratory syncytial virus in Canada in 2003.Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection.Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein.Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar.The impact of respiratory viruses on lung health after preterm birth
P2860

Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.

Item
http://www.wikidata.org/entity/Q35097203
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Palivizumab prophylaxis of res ...... ur years of palivizumab usage.
@ast
Palivizumab prophylaxis of res ...... ur years of palivizumab usage.
@en
type
label
Palivizumab prophylaxis of res ...... ur years of palivizumab usage.
@ast
Palivizumab prophylaxis of res ...... ur years of palivizumab usage.
@en
prefLabel
Palivizumab prophylaxis of res ...... ur years of palivizumab usage.
@ast
Palivizumab prophylaxis of res ...... ur years of palivizumab usage.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Palivizumab prophylaxis of res ...... ur years of palivizumab usage.
@en
P2093
P304
P31
P356
10.1097/00006454-200302001-00007
P433
P478
P577
P698